Common misconceptions surrounding decentralized research often deter sponsors from attaining its key benefits—and this is especially true for small or emerging biotechs with limited shots on goal. But by separating fact from fiction and understanding how to identify fit for purpose solutions, these companies can lay the roadmap for successful implementation of a decentralized clinical trial (DCT) strategy.
Stephanie Gonzalez, Senior Vice President and Head of Global Biotech Solutions at Syneos Health and Alison Holland, Executive General Manager for Decentralized Clinical Trials at Medable debunk some common myths and provide an overview of the benefits decentralization can bring to biotechs.
The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.
For more on DCT strategy, check out these insights:
3 Capabilities to Achieve Optimal Blend of On-Site and Virtual Patient Engagement in DCTs
Not All Decentralized Clinical Trial Capabilities Are Created Equal
4 Ways Decentralized Clinical Trials Can Be Game Changers for Better Patient Outcomes
Hybrid Decentralized Trials in Oncology: A Path to Diversity
